Prevention of recurrent venous thrombosis associated with malignancy

Prevention of recurrent venous thrombosis associated with malignancy refers to secondary thromboprophylaxis aimed at halting the reformation of blood clots, primarily deep vein thrombosis and pulmonary embolism, within the vascular system of patients diagnosed with active cancer

Prevention of recurrent venous thrombosis associated with malignancy refers to secondary thromboprophylaxis aimed at halting the reformation of blood clots, primarily deep vein thrombosis and pulmonary embolism, within the vascular system of patients diagnosed with active cancer

Malignancy induces an aggressive hypercoagulable state driven by tumor-derived procoagulants, such as tissue factor and cancer procoagulant, excessive inflammatory cytokine release, host endothelial injury, and vascular compression This persistent prothrombotic drive, compounded by oncologic interventions like chemotherapy, surgery, and indwelling central venous catheters, places affected individuals at a significantly higher risk of clot recurrence and associated morbidity compared to non-cance...

Malignancy induces an aggressive hypercoagulable state driven by tumor-derived procoagulants, such as tissue factor and cancer procoagulant, excessive inflammatory cytokine release, host endothelial injury, and vascular compression

This persistent prothrombotic drive, compounded by oncologic interventions like chemotherapy, surgery, and indwelling central venous catheters, places affected individuals at a significantly higher risk of clot recurrence and associated morbidity compared to non-cancer populations